• Non-opioid painkiller – pre-clinical stage
  • Lasts up to 300% longer than leading competitor*
  • 22 U.S. Patents


InSitu Biologics is currently in the pre-clinical stage

InSitu Biologics is currently raising capital to fund clinical trials.

We are currently accepting reservations for the purchase of our stock. When we re-open our Stock Offering, we will contact you at the email you provide us, so you can convert your reservation to an investment. Thank you

Learn More About Investing

Who We Are

InSitu Biologics is an emerging biotech company focusing on development of AnestaGel™, a long-lasting and long-acting non-opiate painkiller. The sustained release drug AnestaGel is expected to be used in post-operative surgical procedures. AnestaGel may be a solution in relieving pain for broken bones, cosmetic surgery, hip/knee replacements, hernia, and more.

Latest News & Updates

Pre-Clinical Results

As compared to EXPAREL (Pacira, Inc.), the industry leading post-operative pain treatment.

300% Longer

Initial animal study revealed AnestaGel™ lasted up to 300% longer

8x More Capacity

AnestaGel™ carried 8 times more payload

72+ Hours

AnestaGel™ had full nerve block beyond 72 hours

See our study at the Journal of Pain Research


  • 2016

    Filed additional patent(s)

    White Paper published

    Completed maximum dosing study with no toxicity

    Presented at PODD-Boston

  • 2017

    Completed first GLP study

    Proved more pain relief compared to Exparel in pre-clinical study

    GLP publication accepted

    Raised over $400k

  • 2018

    Completed Financial Audit
    Converted all debt
    Filed $10,000,000 RegA+ Offering

    Launch RegA+ Offering
    Announce GLP Paper by Hutchins & Taylor

    Begin Phase 1 program manufacturing

    Announce final GLP Study results

  • 2019

    SEC valuation incorporating Animal Care Market opportunity

    Submit GLP results for Peer-Review

    FDA Pre-IND meeting

    Expect approval for Phase 1 Clinical Study of AnestaGel

The Executive Team

Meet the InSitu Biologics Executive Team

James Segermark


Jim has been the founder, inventor, investor, and owner operator in many med-tech ventures. Jim began working on the Matrix technology in 2007 and co-founded InSitu Biologics in 2014. Jim is an inventor on over 40 issued patents for medical products, and specializes in the total enterprise of bringing proprietary products from “just an idea” through design, scaled up manufacturing, and “to the patient”. Jim earned his Bachelor of Science from Carroll University in Waukesha, Wisconsin and his MBA from Cardinal Stritch University in Milwaukee.

Bill Taylor

Chief Scientist

Bill is a Co-Founder of InSitu Biologics, beginning his work on the Matrix in 2007. Bill is a successful medical product development programs manager and scientist, and has been awarded over $900k in government research grants, and authored industry papers in chemical remediation and demilitarization utilizing biological systems. Bill has his Bachelor of Science from the University of Minnesota with a double major in Chemical Engineering and Biology.